Hormone Therapy Insights

Overview

This follow-up Q&A session addressed additional questions from a prior webinar on progesterone, focusing on hormone therapy in women, evidence-based approaches, and clinical experiences. Experts discussed protocols, testing, dosing, misconceptions, age considerations, and practical management of hormone therapies.

Session Introduction & Context

• The session is a follow-up Q&A on missing clinical knowledge regarding progesterone in menopause management.
• Panelists include Jill Shamalleski, Phyllis Bronson, and Carol Peterson, who have extensive backgrounds in biochemistry, pharmacy, and hormone therapy.
• The session prioritizes previously submitted questions and is recorded for later sharing.

Panelist Backgrounds & Philosophy

• Panelists come from both traditional and integrative medicine backgrounds.
• They emphasize grounding interventions in scientific evidence, while recognizing individual variability and the emotional-relational context of hormone therapy.
• They advocate empowering women to make informed, individualized health decisions.

Key Clinical Questions & Insights

• Transitioning Off SSRIs:

  • No universal protocols for using progesterone while discontinuing SSRIs; hormone balancing and nutritional support are central.
  • SSRI discontinuation should be individualized and sometimes requires slow tapering with specialist guidance.

• Progesterone & Breast Inflammation:

  • Higher doses (>200 mg oral) of progesterone do not typically cause breast inflammation; progesterone is anti-inflammatory.
  • Combining topical progesterone and iodine can alleviate breast tenderness and fibrocystic changes.

• Testing & Dosing of Progesterone:

  • Symptoms are a more reliable indicator of adequate progesterone than single-lab values or hormone ratios.
  • Transdermal progesterone is highly effective for mood; oral is often sedating due to unique metabolites.
  • Typical clinical doses are individualized and may exceed standardized recommendations.

• Estrogen-Progesterone Relationship:

  • Progesterone does not downregulate estrogen receptors to the point of causing deficiency symptoms; needs for both hormones must be individually assessed.
  • Symptoms that emerge after initial benefit may mean a need for dose adjustment or delivery method change.

• Absorption & Application of Progesterone:

  • Smaller skin application areas may enhance absorption due to concentration gradient; site rotation is not critical.
  • Compounded suppositories and non-U.S. formulations often have fewer additives and may reduce local irritation.

• Older and Younger Patients:

  • Hormone therapy can benefit women into their 70s and beyond, as well as adolescents with severe PMS or irregular cycles (using cyclic progesterone).
  • Individual assessment is key; blanket age criteria are not supported.

• Testing Endometrial Protection:

  • Transvaginal ultrasound is preferred over serum lab levels to confirm endometrial protection with transdermal progesterone use.
  • Initial breakthrough bleeding after starting progesterone is often a sign of endometrial shedding from previous deficiency.

• Special Conditions:

  • Properly dosed progesterone plus iodine may help with fibroids; insufficient progesterone may worsen estrogen-driven growth.
  • Individualized, balanced hormone therapy is essential for conditions such as fibroids or suspected hormone-sensitive tumors.

• Hormone Therapy in Men:

  • Men may benefit from progesterone, especially for sleep and mood; deficiency can parallel symptoms seen in women.

Decisions

• Continue Q&A in future sessions: The panel agreed to host additional sessions if ongoing questions persist.

Action Items

• TBD – Jill Shamalleski: Distribute session replay to registrants and share recommended resources/links.
• TBD – Panelists: Share relevant studies, session references, and resource lists with participants.

Recommendations / Advice

• Taper SSRIs under professional supervision when considering hormone therapy.
• Use symptom tracking, not just lab tests, to guide hormone dosing.
• For persistent symptoms, consider adjusting dose, changing delivery method, or addressing coexisting imbalances (e.g., iodine, glucose).
• Women of all ages with symptomatic hormone deficiency should discuss options with knowledgeable providers.
• Monitor with transvaginal ultrasound if concerned about endometrial protection.

Questions / Follow-Ups

• Monitor for additional questions in the chat/Q&A for inclusion in subsequent sessions.
• Explore further research on progesterone’s metabolic impact and detoxification pathways (e.g., glucuronidation).